{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Parker K"],"pubmed_abstract":["The SS18-SSX fusion protein is an oncogenic driver in synovial sarcoma. At the molecular level, SS18-SSX functions as both an activator and a repressor to coordinate transcription of different genes responsible for tumorigenesis. Here, we identify the proto-oncogene <i>FYN</i> as a new SS18-SSX target gene and examine its relation to synovial sarcoma therapy. FYN is a tyrosine kinase that promotes cancer growth, metastasis and therapeutic resistance, but SS18-SSX appears to negatively regulate <i>FYN</i> expression in synovial sarcoma cells. Using both genetic and histone deacetylase inhibitor (HDACi)-based pharmacologic approaches, we show that suppression of SS18-SSX leads to <i>FYN</i> reactivation. In support of this notion, we find that blockade of FYN activity synergistically enhance"],"journal":["Frontiers in cell and developmental biology"],"pagination":["1422452"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11264242"],"repository":["biostudies-literature"],"pubmed_title":["Combination of HDAC and FYN inhibitors in synovial sarcoma treatment."],"pmcid":["PMC11264242"],"pubmed_authors":["Anchondo G","Kondo T","Parker K","Zhang Y","Smith A","Su L","Guerrero Pacheco S"],"additional_accession":[]},"is_claimable":false,"name":"Combination of HDAC and FYN inhibitors in synovial sarcoma treatment.","description":"The SS18-SSX fusion protein is an oncogenic driver in synovial sarcoma. At the molecular level, SS18-SSX functions as both an activator and a repressor to coordinate transcription of different genes responsible for tumorigenesis. Here, we identify the proto-oncogene <i>FYN</i> as a new SS18-SSX target gene and examine its relation to synovial sarcoma therapy. FYN is a tyrosine kinase that promotes cancer growth, metastasis and therapeutic resistance, but SS18-SSX appears to negatively regulate <i>FYN</i> expression in synovial sarcoma cells. Using both genetic and histone deacetylase inhibitor (HDACi)-based pharmacologic approaches, we show that suppression of SS18-SSX leads to <i>FYN</i> reactivation. In support of this notion, we find that blockade of FYN activity synergistically enhance","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-06-01T01:16:26.572Z","creation":"2025-06-01T01:16:26.572Z"},"accession":"S-EPMC11264242","cross_references":{"pubmed":["39045458"],"doi":["10.3389/fcell.2024.1422452"]}}